Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated 2 days ago
Fierce Biotech Layoff Tracker 2026: Ensoma sheds more staff; Emergent lays off 93 employees
2 days ago
As always, if you know of layoffs occurring at a biotech, please...
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
2 days ago
Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill...
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
2 days ago
Boston biotech Ensoma is doubling down on its lead gene therapy for...
‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
3 days ago
Novo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the...
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
3 days ago
Novo Nordisk CFO Karsten Munk Knudsen joins “The Top Line” to discuss...
BioMarin axes $270M rare disease asset after missing phase 3 endpoint
3 days ago
BioMarin Pharmaceutical has ended development of BMN 401 in all indications months...
Roche adds cyclospora PCR tests as outbreak widens
3 days ago
Roche is launching new tests for cyclospora as an outbreak linked to...
Chutes & Ladders—BioNTech brings in Sobi CEO
3 days ago
After a six-month wait, BioNTech has finally filled its vacant CEO spot...
Double shot of Vistagen’s anxiety nasal spray can’t beat placebo in ph. 2 trial
3 days ago
Following a string of clinical setbacks, Vistagen’s nasal spray for social anxiety...
PacBio CEO steps down as Q2 loss widens
3 days ago
PacBio has promoted an internal veteran to CEO after Christian Henry stepped...
Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug
3 days ago
Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its...
BioVie’s stock sinks 50% as company uses composite endpoint to make case for Parkinson’s program
3 days ago
BioVie has hailed phase 2 data as evidence that bezisterim could represent...